We Work for Health | Washington

03/20/2026

"These policies restrict the availability of breakthrough treatments for Japanese patients and place a greater share of the cost of global medical innovation on American patients."

puts the U.S. at an international disadvantage:

President Trump will soon welcome Prime Minister Sanae Takaichi to Washington for a high-profile U.S.-Japan summit. Given what’s at stake for patients and

03/18/2026

"Voluminous evidence confirms that implementing MFN price controls will reduce investment in research, development, and discovery of beneficial new drugs."

Read about the economic impacts of on American industries: https://www.washingtonexaminer.com/op-eds/4488743/trump-most-favored-nation-threatens-us-competitiveness-china/

03/18/2026

"That free-riding is unfair. But it’s also a very tangible threat to our economy and our health. If American companies are losing tens of billions in revenue, they cannot hire as many workers or develop as many life-saving treatments."

https://www.washingtonexaminer.com/opinion/4486552/drug-pricing-top-of-agenda-trump-takaichi-meeting/

03/13/2026

"When insurers control both the PBM that determines which drugs are “preferred” and the pharmacies where prescriptions must be filled, corporate policy can override the doctor‑patient relationship."

operate as a dangerous middleman when unchecked: https://www.wyomingnews.com/opinion/guest_column/leslie-health-care-decisions-should-be-made-close-to-home-not-in-corporate-boardrooms/article_75697df3-df8a-429e-a56b-d4efd0fcd558.html

03/11/2026

"Today's drug pricing proposals overlook this fragile balance. If Medicare price controls or MFN models drive down reimbursement rates while acquisition costs stay the same — or climb higher due to tariffs — independent practices will be left underwater."

https://www.nola.com/opinions/guest_columns/guest-column-drug-pricing-reforms-cannot-neglect-independent-practitioners/article_03ea9366-87d9-40f9-a2ca-127fabba76c1.html

03/10/2026

"It would be a tragic mistake for the U.S. to move forward with a well-intentioned but flawed plan to tie drug prices to European health systems where QALY-based cost-effectiveness frameworks influence pricing and reimbursement decisions."

https://www.thewellnews.com/opinions/dont-adopt-europes-discriminatory-drug-pricing-against-individuals-with-down-syndrome/

03/06/2026

"China is dramatically expanding biotech funding and commercialization through state-backed programs, while Europe pairs aggressive price controls with heavy public investment in life sciences infrastructure."

policy won't work for the U.S.:

By failing to account for the true cost and risk of medical innovation, MFN would undermine investment, slow research, and jeopardize jobs, patients, and our position as a global leader

03/04/2026

"CBO originally estimated that the Center for Medicare and Medicaid Innovation would save $2.8 billion from 2011 to 2020, but the bureaucracy ended up costing taxpayers $5.4 billion."

More on the "Taxpayer's State of the Union":

The state of the union is far better than it was under President Biden.

03/02/2026

Voters have made their voices heard about the importance of transparency and access.

Here's what they said: https://www.americasnewmajorityproject.net/p/insurer-and-middleman-crackdowns?utm_source=post-email-title&publication_id=6887949&post_id=189143946&utm_campaign=email-post-title&isFreemail=false&r=16tk4&triedRedirect=true&utm_medium=email

02/27/2026

"By seeking to anchor US prices to international benchmarks, however, the proposals create a fundamental policy tension between US safeguards against use of QALYs in Medicare, and the adoption of QALY-based decisions from other countries."

https://www.healthaffairs.org/content/forefront/qaly-paradox-unintended-consequence-most-favored-nation-drug-pricing

02/25/2026

Remember, government price-setting risks shifting leadership in biotech innovation from the U.S. to other countries.

Read about the possible impacts in this op-ed by Rich Bagger of Drug Wonks:

Republican U.S. Rep. Nicole Malliotakis has consistently raised concerns about the dangers of onerous federal regulations that stifle innovation and economic

02/25/2026

The State of the Union made it clear: Drug pricing is on President Donald J. Trump's mind.

Instead of ensuring low prices make it to patients, Most Favored Nation drug pricing could halt innovation and catapult China to international leadership in biopharma.